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Abstract
Background: The purpose of our study was to investigate the immunohistochemical expression
of TGF-β1 and p27 in pancreatic adenocarcinomas and to compare the findings with the
clinicopathological features and survival. We also aimed to evaluate the expression of TGF-β1 and
p27 in the context of other cell cycle and proliferation markers such as cyclin D1 and Ki-67.
Methods:  We examined TGF-β1 and p27 expression immunohistochemically in 63 cases of
invasive ductal adenocarcinoma of the pancreas. Standard streptavidin-biotin immunperoxidase
method was used for immunostaining and the stained slides were examined microscopically using
semiquantitative criteria.
Results: TGF-β1 stained the cytoplasms of the tumor cells in 43 cases [68.3%]. There was a
statistically significant difference among TGF-β1 staining scores in terms of clinicopathologic factors
such as blood vessel invasion, stage and distant metastasis [p < 0.05]. Of the 63 tumors evaluated
23 [36.5%] were positive for p27 within the nucleus. An inverse correlation was found between
p27 immunoreactivity and grade [p < 0.05]. But no significant correlation was found between p27
and other parameters. Among the patients with survival data 27 patients had RO resections and
these cases were considered in survival analysis. In the univariate analysis, neither TGF-β1 nor p27
expression was related with patient survival.
Conclusion: Our findings suggest that in pancreatic carcinoma, TGF-β1 expression is related to
tumor growth and metastasis. But it is not associated with cell cycle proteins. p27 expression is
reduced in pancreatic adenocarcinomas and decreased protein levels of p27 may play a role in the
differentiation of pancreatic cancer.
Background
Pancreatic cancer is a malignant tumor with an extremely
poor prognosis. This tumor is highly aggressive and
patients with this form of cancer have a short survival after
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diagnosis. Even when the tumor is localized, the mean
survival time after radical resection varies from 10 to 20
months [1]. The mechanisms of the aggressive growth and
metastasis are not yet extensively understood.
Several studies indicated that proliferative activity of
tumor cells, as well as tumor angiogenesis, inactivation of
tumor supressor genes, overexpression of growth factors
may play role in pancreatic carcinogenesis and may help
to predict patient outcome [2-8]. Recent studies denoted
that alterations in growth factors and growth factor recep-
tors seem to influence the biologic behaviour of pancre-
atic cancer cells [2]. Growth factors are involved in
carcinogenesis, where they influence a variety of functions
including cell proliferation, invasion, metastasis, angio-
genesis, local immune system functions, and extracellular
matrix formation [2]. Growth factors do not only stimu-
late cell proliferation, but they may also act as growth
inhibitors, depending on the cell type and the stimulatory
pathway that is involved. Transforming growth factor-β
[TGF-β] is such an example, being a growth stimulator in
fibroblastic cells with TGF-β receptors, but a negative reg-
ulator in epithelial cells.
TGF-β belongs to a family of homologous polypeptides
that includes three major isoforms [TGF-β1, TGF-β2, TGF-
β3]. It has been reported that TGF-β influence different
cell functions, including growth, proliferation and differ-
entiation. It can influence cancer growth in various ways,
such as by stimulating angiogenesis, suppressing cancer-
directed immune functions, increasing the expression of
adhesion molecules and extracellular matrix components
[9]. Human pancreatic cancer cells may exhibit loss of
responsiveness to TGF-β-mediated growth inhibition as a
consequence of altered TGF-β expression as well as a result
of postreceptor alterations [10]. It has also been demon-
strated that TGF-β induced cell cycle arrest can be partially
attributed to the regulatory effects of TGF-β on both the
expression and activity of cyclin-dependent kinase inhibi-
tors [CDKI] such as p21 and p27. The binding of these
inhibitors to spesific cyclin-dependent kinase [CDK] com-
plexes blocks their activity and causes cell cycle arrest
[11,12].
Alterations in cell cycle regulatory mechanisms play an
important role in the tumor development. Cell cycle pro-
gression is regulated by a series of cyclins, CDKs and
CDKIs. p27, a member of the Cip/Kip family is a low
molecular weight CDKI, which is able to arrest cell cycle
progression by complexing CDKs and their activity [13].
Low p27 expression has been reported to be a poor prog-
nostic factor in a variety of human cancers including pros-
tate, lung, squamous cell carcinomas [13-18].
In this study, we investigated the immunohistochemical
expressions of TGF-β1 and p27 in pancreatic adenocarci-
nomas and the results were correlated with the clinico-
pathologic characteristics of the cases and the patients'
survival to find out if these factors could be used as an
additional predictor of the disease extent and patient out-
come. Additionally, we evaluated the expression of TGF-
β1 and p27 in the context of other cell cycle and prolifer-
ation markers; cyclin D1 and Ki-67.
Methods
Pancreatic cancer tissues were obtained from 63 patients
[36 female, 27 male] undergoing pancreatic surgery for
primary pancreatic adenocarcinoma in Dokuz Eylül Uni-
versity Hospital between the years 1996 and 2003. The
mean age of the patients was 62 years, with a range of 42–
82. The patients were not subjected to any sort of chemo-
therapy or radiation therapy prior to resection. Surgical
procedures consisted of either distal pancreatectomy or
Whipple procedure. Some of the patients underwent pal-
liative surgical treatment. The histological diagnosis of
each specimen was provided by standard light micro-
scopic evaluation of the routinely processed and parafin
embedded tissues. The H&E stained slides of each case
were taken from the pathology archieves and reviewed by
two pathologists without knowledge of the patients' out-
come. The tumors were typed as proposed by WHO and
graded as well, moderate or poorly differentiated. Interna-
tional Union Against Cancer [UICC] TNM classification
system [sixth edition] was used for staging. Staging was
based on the information at the time of diagnosis. Lym-
phatic vessel, blood vessel and perineural invasions as
well as lymph node, resection margin and adjacent organ
involvements were reevaluated in each tumor.
Immunohistochemistry
The most representative tumor tissue block was chosen
from each case and 5 µm sections were taken to poly-L
lysin coated slides for immunuhistochemical staining.
Standard streptavidin biotin immunperoxidase method
was used for immunostaining with TGF-β1 [Santa Cruz,
sc-146, California, USA], p27Kip1 [DAKO, Glostrup, Den-
mark, M7203, dilution: 1/50], cyclin D1 [NeoMarkers,
Fremont CA, Clone DCS-6, MS210-P, dilution: 1/50] and
Ki-67 [NeoMarkers, Fremont CA, Clone MB67, MS1006-
A, dilution: 1/50] antibodies. This indirect immunoperox-
idase staining procedure was performed at room temper-
ature. Appropriate tissue sections known to react with
both antibodies as positive controls for each primary anti-
body were also stained simultaneously.
Analysis of immunohistochemical data
TGF-β1 scoring
The stained slides were examined microscopically using
the following parameters and semiquantitative criteria.BMC Cancer 2005, 5:98 http://www.biomedcentral.com/1471-2407/5/98
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Cytoplasmic immunostaining in tumor cells were
accepted as positive. For evaluation of the immunohisto-
chemical results, the intensity of the immunoreaction and
the number of the immunoreactive cancer cells were
scored on the tissue slides. The intensity of the immuno-
reaction was classified into 4 levels: 0: no staining, 1: weak
staining, 2: moderate staining, 3: intense staining. In addi-
tion, the percentage of the immunoreactive cancer cells
was recorded; 0, negative; 1, less than 33% positive stain-
ing; 2, 33% to 66% positive staining, 3, more than 66%
positive staining. A combined score of 0 to 6 was assigned.
Tumors given a score 0 to 1 were classified as negative;
those given a score of 2 were classified as weakly positive;
a score of 3 to 4 was considered moderately positive; and
a score of 5 to 6 was considered strongly positive [19].
p27 scoring
Approximately 500 cells from the selected area were
counted, and the number and percentage of cells with
nuclear p27 staining were noted. Cells that had either
weak or strong nuclear staining were considered to be pos-
itive for p27 protein expression. Cells without nuclear
staining were considered negative. The percentage of cells
expressing p27 was recorded as the ratio of positive cells-
to-the total number of cells counted. p27 expression was
grouped as high or low. Patients with low p27 expression
had less than 30% of the nuclei in the specimen staining
positive, while those with high levels of p27 expression
had more than 30% of the nuclei staining for the bound
antibody [15].
Ki-67 scoring
Fifty-two cases were stained with Ki-67. Nuclear immu-
nostaining in tumor cells were accepted as positive. At
least 10 fields containing approximately 500 tumor cells
were counted each per case at 400 × magnification. The
number of Ki-67-staining reactive cells in each field was
determined as a percentage of the total number of tumor
cells counted [20].
cyclin D1 scoring
Fifty-two cases were stained with cyclin D1. Nuclear
immunostaining in tumor cells were evaluated according
to Holland et al [21]. Cyclin D1 expression in tumors was
graded as negative: less than 10% of cells stained; 1+: 10–
50% of cells stained; 2+: 50–75% of cells stained and 3+:
more than 75% of cells stained.
Statistical analysis
Data were analyzed by a computer software SPSS for Win-
dows 10.0. A p value <0.05 was considered statistically
significant. Immunohistochemical scores were compared
among prognostic parameter subgroups by the chi-square
and Fishers exact tests. Correlations between non-para-
metric and parametric values were tested with Kendall's
tau-b and Spearman correlation tests respectively. The
effect of prognostic and immunohistochemical scores on
the patient survival was tested in potentially curatively
operated patients who had R0 resections, with Cox regres-
sion analysis.
Results
Clinicopathologic features
Clinicopathologic features of the patients is shown in
Table 1. Thirty-six were women, 27 were men. The median
age of the patients was 62 years, with a range of 42–82.
The size of the resected tumors ranged between 1 and 13
cm [median 4.5 cm]. Sixteen tumors were well differenti-
ated, 33 were moderately differentiated, and 14 were
poorly differentiated. Four, 23, 3 and 33 patients had
stage I, II, III and IV disease. Thirty-nine [61.9%] patients
had one and more than one regional lymph node metas-
tasis and 33 [52.4%] patients had distant metastasis.
Among resected tumors, 44 [69.8%] showed perineural
invasion, 26 [41.3%] showed lymphatic vessel and 21
[33.3%] showed blood vessel invasion. Survival data were
available for 54 patients. At follow-up, 38 patients
[60.3%] had died of disease. The overall median survival
of these 38 patients was 13 months. Sixteen patients were
still alive with no evidence of disease. The remaining
patients were either lost to follow-up or their death status
Intense [score 6] cytoplasmic TGF-β1 immunoreactivity of  pancreatic ductal carcinoma cells [anti-TGF-β1, original mag- nification, × 400] Figure 1
Intense [score 6] cytoplasmic TGF-β1 immunoreactivity of 
pancreatic ductal carcinoma cells [anti-TGF-β1, original mag-
nification, × 400].BMC Cancer 2005, 5:98 http://www.biomedcentral.com/1471-2407/5/98
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was unknown. Among the patients with survival data 27
patients had RO resections and these cases were consid-
ered in survival analysis.
Immunohistochemical analysis
TGF-β1 stained the cytoplasm of the tumor cells in 43
cases [68.3%] [Figure 1]. Strongly positive staining was
observed in 14 tissues [22.2%] while 19 tumors [30.1%]
were moderately and 10 [15.9%] were weakly positive.
There was a statistically significant positive correlation
among TGF-β1 staining scores in terms of clinicopatho-
logic factors such as blood vessel invasion [p = 0.01], stage
[p = 0.05] and distant metastasis [p < 0.01] [Table 2]. But
the other prognostic parameters did not relate signifi-
cantly with TGF-β1 staining scores. Additionally, we could
not find an association with cyclin D1 [Table 3] and Ki-
67.
p27 immunoreactivity was concentrated within the
nucleus, but concomitant faint cytoplasmic staining was
also observed [Figure 2]. Of the 67 tumors evaluated, 40
[63.5%] were negative, 17 [27%] were assessed to have
low grade and 6 [9.5%] were assessed to have as high
grade p27 staining. Positive staining for p27 was found
dominantly in low-grade tumors [p = 0.02] [Table 2].
Although the number was so small high grade p27 stain-
ing tended to be in low stage tumors [stage grouping was
performed as: I and II as low, III and IV as high], but the
difference was not statistically significant. On the other
hand, there was no association between p27 expression
and other clinicopathologic parameters. In statistical anal-
ysis, there was also no difference between p27 and cyclin
D1 expression and Ki-67.
Forty-nine [77.8%] tumors showed positive nuclear stain-
ing with cyclin D1 while 3 [4.8%] cases showed no stain-
ing. There was a statistically significant difference among
cyclin D1 nuclear staining scores in terms of tumor size [p
= 0.03]. The other prognostic parameters did not relate
significantly with nuclear or cytoplasmic staining with
cyclin D1.
In the whole group, the mean proliferative index of the
tumors were 41.5%, ranging from 2% to 97%. In
statistical analysis, no significant relation was found
between mean proliferative index of the tumors and prog-
nostic parameters.
TGF-β1, p27 and clinical outcome
The median survival time was 13.4 months [range, 0–59
months] for low-expressors and the median survival time
was 13.7 months [range, 1–38 months] for high-
expressors for TGF-β1. The median survival time was 13.6
months [range, 0–59 months] for low-expressors and the
median survival time was 13.4 months [range, 6–26
months] for high-expressors for p27. In the univariate
analysis, neither TGF-β1 nor p27 expression was related
with patient survival.
Discussion
Several tumor markers are studied to explain the mecha-
nism of pancreatic carcinogenesis. Dysregulation of the
normal cell cycle machinery is integrated to the neoplastic
process and there is evidence implicating loss of cell cycle
control in the development and progression of most
human cancers, including pancreatic cancer. Regulation
of cell cycle depends on the complex association between
cyclin, CDK and CDKIs. According to their effects on cell
cycle progression, these regulators qualify as proto-onco-
genes [cyclin D1, D2, E] or tumor supressors [p21, p27].
Recently, studies have been performed in demonstration
of p21, p27, cyclin D in tumors [17,22-25].
p27 is a CDKI that negatively regulate cyclin and its low
expression results in proliferation of DNA damaged cells.
Table 1: Clinicopathological features
Number of patients [%]
Sex
Female 36 [57.1]
Male 27 [42.9]
Histologic grade
Well 16 [25.4]
Moderate 33 [52.4]
Poor 14 [22.2]
Stage
I 4 [6.4]
II 23 [36.5]
III 3 [4.8]
IV 33 [52.4]
Lymph node metastasis
Negative 24 [38.1]
Positive 39 [61.9]
Perineural invasion
Negative 19 [30.2]
Positive 44 [69.8]
Distant metastasis
Negative 30 [47.6]
Positive 33 [52.4]
Total 63 [100]BMC Cancer 2005, 5:98 http://www.biomedcentral.com/1471-2407/5/98
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Recent studies indicate that reduced expression of p27 is
an independent predictor of poor outcome in cancers
such as oral tongue squamous cell carcinoma, prostate
cancer, gastrointestinal tract cancers, and even laryngeal
precancerous lesions [14-18,26,27]. Lu et al demonstrated
that loss of p27 expression independently predicts a poor
prognosis for patients with resectable pancreatic adeno-
carcinomas [24]. Also anomalous overexpression of p27
in human pancreatic endocrine tumors were reported
[25]. Inverse correlation between p27 expression and
tumor grade, lymph node metastasis and stage of tumor
was reported [14]. In the present study, we found positive
staining for p27 in only minority of pancreatic adenocar-
cinoma cases and the staining was weak indicating that
p27 is down-regulated during neoplastic process in pan-
creas. Additionally, although the difference was not statis-
tically significant, p27 was dominantly expressed in low
stage tumors. These results confirmed the previous
reports. In a few reports, p27 and p21 staining did not cor-
relate significantly with any clinicopathologic parameters
[28,29], but there was an association between p27 and
cyclin D1 expression indicating that the balance between
the two opposing regulators was important for the end
result of cell cycle progression [22]. Del Pizzo and Armen-
gol found a positive correlation between p27 and cyclin E
[30,31]. In the present study we could not find any rela-
tion between p27 and cyclin D1 expression.
It is well established that cell proliferation kinetics are
important in predicting the prognosis of various tumors.
Recenty, the highly proliferative activity as measured by
Ki-67 antigen has been shown to correlate with a reduced
p27 expression in various tumors suggesting that
decreased expression of p27 may play important role in
the increased cell turnover [32]. But the lack of correlation
between cell cycle regulators and proliferation index has
Table 2: Tissue marker expressions and tumor characteristics
TGF-β1 p 27 Cyclin D1
Variables 012 3 p 0 12 p 0 1 p
Sex
Female 13 7 8 8 0.68 26 6 4 0.10 0 31 0.06
Male 7 3 11 6 14 11 2 3 18
Grade
Well 8 2 5 1 0.58 12 3 1 0.02 2 13 0.42
Moderate 7 6 10 10 23 9 1 1 25
P o o r 524 3 5 54 0 1 1
Stage
I 400 0 0 . 0 5 3 100 . 9 7 1 3 0 . 3 0
II 11 4 8 0 14 6 3 0 18
I I I 011 1 3 00 0 3
IV 5 5 10 13 20 10 3 2 25
Lymph node m.
Negative 10 6 7 4 0.34 19 7 1 0.34 3 19 0.23
Positive 8 3 6 9 15 7 4 0 22
Perineural inv.
Negative 3 1 3 2 0.95 6 1 2 0.21 1 7 0.47
Positive 16 8 11 9 28 13 3 2 32
Distant met.
Negative 15 5 9 1 <0.01 9 4 0 0.51 2 8 0.09
Positive 5 5 10 13 31 13 6 1 41
Blood vessel in.
Negative 14 6 10 4 0.01 23 9 2 0.62 3 25 1
Positive 4 3 5 9 13 5 3 1 17
Table 3: Relationships between TGF-β1, p 27 and cyclin D1
TGF-β1 immunoreactivity
0 1 2 3 p value
Cyclin D1
01 1 0 1 0 . 6
11 9 6 1 2 1 2
p 27
01 4 6 1 3 7 0 . 7
15 3 4 5
21 1 2 2BMC Cancer 2005, 5:98 http://www.biomedcentral.com/1471-2407/5/98
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been also reported in some studies [22,27,31]. In the
present study, we did not find any significant association
between p27, cyclin D1 and proliferative activity. Cell
cycle regulators might be more closely related with differ-
entiation than proliferative activity, so induction of them
may perhaps be necessary, but probably not sufficient for
inhibition of cell cycle.
Growth factors, such as TGF-β and growth factor receptors
have been shown to be overexpressed in a variety of can-
cers [10,33]. TGF-β can act as both a tumor suppresor and
as a stimulator of tumor progression, invasion and metas-
tasis. TGF-β inhibits normal cell proliferation and this
effect is induced by binding specific cell receptors, type I
[TβR-IALK5] and type II [TβR-II]. Both receptors were
present in most cancer tissues and presence of them was
associated with advanced tumor stage [10]. In pancreatic
cancers, all three TGF-β isoforms are expressed at high lev-
els and the presence of TGF-β isoforms is associated with
shorter postoperative survival [34]. TGF-β isoforms were
also markedly increased in hepatocellular carcinoma and
prostate carcinoma [35-37]. Overproduction of TGF-β1
and loss of TGF-β-RII expression were found to be associ-
ated with poor clinical outcome [10]. Nevertheless several
reports have indicated that TGF-β1 expression showed a
significant correlation with low grade tumors and with
longer survival time [19,29]. In the present study there
was a statistically significant difference between TGF-β1
staining scores in terms of clinicopathologic factors such
as blood vessel invasion, distant metastasis and stage. Our
analysis revealed that overproduction of TGF-β1 corre-
lates with tumor progression and metastasis. In the
present study we could not find a correlation between
TGF-β1 and p27 expression. TGF-β1 might influence can-
cer growth in other ways rather than cell cycle proteins.
Hashimoto demonstrated a significant correlation
between TGF-β1 and p21 expression and stated that the
evaluation of TGF-β1 and p21 expression might be an
effective tool in the prediction of the prognosis of patients
with pancreatic cancer [29]. Grau and Ito also reported
that TGF-β1 induces p21 expression in pancreatic cancer
cells [11,38]. p21 may play more important role in the
biology of pancreatic cancer than p27. We found no cor-
relation between TGF-β1 and other proliferation markers
studied. TGF-β1 induction of other CDKIs, such as p15
may partially participate in the inhibition of mitosis.
There is conflicting data in the literature about the corre-
lation of TGF-β1 expression with survival in pancreatic
cancer. In most series, the presence of TGF-β1 is associated
with shorter postoperative survival [34], although in some
other studies TGF-β1 expression showed a significant cor-
relation with longer survival time [19,29]. On the other
hand, there are reports indicating that TGF-β expression
has no association with survival [39]. In the present study,
to have the same treatment protocol only the patients
which had RO resections were considered in survival anal-
ysis and TGF-β1 and p27 expression did not show a signif-
icant influence on the survival of patients. The small
number of the patients may be the reason not to have
definitive conclusions. TGF-β's role in controlling cellular
growth and differentiation is very complex. In this study,
findings may suggest that TGF-β1 may be a factor in the
extention of the disease in pancreatic adenocarcinomas.
But, progress may depend on the participation of other
regulatory signals. Additional parameters related to prog-
nosis and standard prognostic parameters are needed in
the prediction of the disease outcome. Further studies that
involve screening a larger number of patients with inva-
sive disease will be required to establish the potential clin-
ical usefulness of cell cyle regulators as prognostic markers
in pancreatic cancer.
Conclusion
In the present study we examined the expression paterns
of TGF-β1 and p27, which involved in cell cycle regula-
tion, in pancreatic adenocarcinoma. Our findings suggest
that in pancreatic carcinoma, TGF-β1 overexpression is
more pronounced in metastatic and progressive ones. p27
expression is reduced in pancreatic adenocarcinomas and
it may play a role in the differentiation of pancreatic can-
cer. Therefore, evaluation of these proteins might be use-
ful in determining the agressive capacity of these tumors
at an earlier stage.
High level nuclear p27 immunoreactivity of pancreatic carci- noma cells [anti-p27, original magnification, × 400] Figure 2
High level nuclear p27 immunoreactivity of pancreatic carci-
noma cells [anti-p27, original magnification, × 400].BMC Cancer 2005, 5:98 http://www.biomedcentral.com/1471-2407/5/98
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